K-ras gene mutation as a predictor of cancer cell responsiveness to metformin

Molecular Medicine Reports

Volumn 8, Issue 3, 2013, Pages 763-768

  Ma, Yu ^a   Guo, Fu Chun ^a   Wang, Wei ^a   Shi, Hua Shan ^a   Li, Dan ^a   Wang, Yong Sheng ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Epidermoid cancer; K ras; Metformin; Molecular targeting; Non small cell lung cancer; Pancreatic cancer

Indexed keywords

K RAS PROTEIN; METFORMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE K RAS; PREDICTOR VARIABLE; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; LUNG NEOPLASMS; METFORMIN; MICE; MICE, NUDE; MUTATION; RAS PROTEINS; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84881161281     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1596     Document Type: Article

References (35)

1. Vigneri P, Frasca F, Sciacca L, Pandini G and Vigneri R: Diabetes and cancer. Endocr Relat Cancer 16: 1103-1123, 2009.
2. Gallagher EJ and LeRoith D: Insulin, insulin resistance, obesity, and cancer. Curr Diab Rep 10: 93-100, 2010.
3. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C and Menendez JA: Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle 9: 1057-1064, 2010.
4. Gonzalez-Angulo AM and Meric-Bernstam F: Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res 16: 1695-1700, 2010.
5. Zakikhani M, Dowling R, Fantus IG, Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66: 10269-10273, 2006.
6. Jones RG, Plas DR, Kubek S, et al: AMP-Activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18: 283-293, 2005.
7. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA and Bae-Jump VL: Metformin is a potent inhibitor of endometrial cancer cell proliferation - implications for a novel treatment strategy. Gynecol Oncol 116: 92-98, 2010.
8. Kisfalvi K, Sinnett-Smith J, Eibl G and Rozengurt E: Metformin inhibits growth of human pancreatic cancer cells in vitro and in vivo. Pancreas 38: 1016-1017, 2009.
9. Bodmer M, Becker C, Jick SS and Meier CR: Metformin does not alter the risk of lung cancer: a case-control analysis. Lung Cancer 78: 133-137, 2012.
10. Bodmer M, Becker C, Meier C, Jick SS and Meier CR: Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev 21: 280-286, 2012.
11. Buzzai M, Jones RG, Amaravadi RK, et al: Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67: 6745-6752, 2007.
12. Reuter CW, Morgan MA and Bergmann L: Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 96: 1655-1669, 2000.
13. Cox AD and Der CJ: Ras family signaling: therapeutic targeting. Cancer Biol Ther 1: 599-606, 2002.
14. Friday BB and Adjei AA: K-ras as a target for cancer therapy. Biochim Biophys Acta 1756: 127-144, 2005.
15. Legaspi A, Jeevanandam M, Starnes HF Jr and Brennan MF: Whole body lipid and energy metabolism in the cancer patient. Metabolism 36: 958-963, 1987.
16. Blum R and Kloog Y: Tailoring Ras-pathway - inhibitor combinations for cancer therapy. Drug Resist Updat 8: 369-380, 2005.
17. Skolnik EY, Batzer A, Li N, et al: The function of GRB2 in linking the insulin receptor to Ras signaling pathways. Science 260: 1953-1955, 1993.
18. Noguchi T, Matozaki T, Horita K, Fujioka Y and Kasuga M: Role of SH-PTP2, a protein-tyrosine phosphatase with Src homology 2 domains, in insulin-stimulated Ras activation. Mol Cell Biol 14: 6674-6682, 1994.
19. Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoël MJ, et al: Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene 20: 252-259, 2001.
20. Medema RH, de Vries-Smits AM, van der Zon GC, Maassen JA and Bos JL: Ras activation by insulin and epidermal growth factor through enhanced exchange of guanine nucleotides on p21ras. Mol Cell Biol 13: 155-162, 1993.
21. Lehman TA, Bennett WP, Metcalf RA, et al: p53 mutations, ras mutations and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res 51: 4090-4096, 1991.
22. Watanabe M, Nobuta A, Tanaka J and Asaka M: An effect of K-ras gene mutation on epidermal growth factor receptor signal transduction in PANC-1 pancreatic carcinoma cells. Int J Cancer 67: 264-268, 1996.
23. Oliveras-Ferraros C, Cufi S, Queralt B, et al: Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells. Br J Cancer 106: 1406-1414, 2012.
24. Iivanainen E, Lauttia S, Zhang N, et al: The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels. Microvasc Res 78: 278-285, 2009.
25. Bartrons R and Caro J: Hypoxia, glucose metabolism and the Warburg's effect. J Bioenerg Biomembr 39: 223-229, 2007.
26. Feig LA and Buchsbaum RJ: Cell signaling: life or death decisions of ras proteins. Curr Biol 12: R259-R261, 2002.
27. Ferla R, Haspinger E and Surmacz E: Metformin inhibits leptin-induced growth and migration of glioblastoma cells. Oncol Lett 4: 1077-1081, 2012.
28. Adjei AA: Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93: 1062-1074, 2001.
29. Wang W and Guan KL: AMP-activated protein kinase and cancer. Acta Physiol (Oxf) 196: 55-63, 2009.
30. Carling D: AMP-activated protein kinase: balancing the scales. Biochimie 87: 87-91, 2005.
31. Mahoney CL, Choudhury B, Davies H, et al: LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition. Br J Cancer 100: 370-375, 2009.
32. Ben Sahra I, Regazzetti C, Robert G, et al: Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res 71: 4366-4372, 2011.
33. Kalender A, Selvaraj A, Kim SY, et al: Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 11: 390-401, 2010.
34. Cox AD and Der CJ: Farnesyltransferase inhibitors: promises and realities. Curr Opin Pharmacol 2: 388-393, 2002.
35. Li D: Metformin as an antitumor agent in cancer prevention and treatment. J Diabetes 3: 320-327, 2011.